Genetics evaluations improve risk prediction in retinoblastoma patients

Article

Incorporating genetics into the treatment plan of retinoblastoma patients improves risk prediction and ensures accurate evaluations.

Incorporating genetics into the treatment plan of retinoblastoma patients improves risk prediction and ensures accurate evaluations, claims a study in the Archives of Ophthalmology.

Dr Shweta U. Dhar et al., Department of Ophthalmology, The Methodist Hospital, Houston, Texas, USA, conducted a retrospective study on 90 retinoblastoma patient evaluations performed over 8 years. A multidisciplinary team was created from an ophthalmologist, paediatric oncologists, an ophthalmic pathologist, a geneticist and genetics counsellors.

Of the patients evaluated, 81 probands were discovered, including 34 bilateral and 47 unilateral. Nine of the total patients were assessed due to a positive family history of retinoblastoma.

In 51 out of 81 bilateral and unilateral patients genetic testing was successfully completed. An RB1 mutation was found in the peripheral blood samples of 5 out of 30 patients with unilateral disease. Sporadic retinoblastoma was identified in 7 out of 30 patients undergoing mutation analysis.

Genetic testing revealed that, out of 48 patient family members from 21 families, 42 tested negative for familial mutation and 6 tested positive. The results emphasized the value of genetic evaluation in the management plan for retinoblastoma patients.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.